Clinical trials: Flu
Vaccine Refusal
Promoting Altruism to Enhance Vaccine Acceptance
Subjects enrolled in this study are eligible for the seasonal influenza vaccine. The purpose of this research study is to figure out if increasing individuals' awareness of the benefits of herd immunity, specifically to the local…
- Trial name
- NCT04568590
- Testing
- educational intervention
- Where
- United States
- Volunteers
- 510 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Immunocompromised Patients, Safety of Pandemic Influenza A (H1N1)Vaccine
Evaluation of Pandemic Influenza A (H1N1) Vaccine in Chronic and or Immunocompromised Patients, Elderly and Pregnants
The objective of this study is to describe the safety and immunogenicity of a non-adjuvanted vaccine against pandemic influenza A (H1N1)in patients with chronic and or immunocompromised disease, elderly and pregnants.
- Conditions
- Immunocompromised Patients, Safety of Pandemic Influenza A (H1N1)Vaccine, Immunogenicity of Pandemic Influenza A (H1N1)Vaccine
- Trial name
- NCT01218685
- Testing
- Split inactivated A/California/7/2009 (H1N1) (NYMC X-179A) VIRUS
- Where
- Brazil
- Volunteers
- 1,152 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Influenza, COVID-19
Analysis of the Determinants of Adherence to Coadministration of Flu Vaccination With the Booster of COVID-19 Vaccine
This study investigates healthcare workers' attitudes towards co-administering COVID-19 and seasonal influenza vaccines, a method supported globally for its efficiency and potential to lessen healthcare burdens.
- Trial name
- CoVFlu (NCT05781191)
- Testing
- COMIRNATY
- Where
- Italy
- Volunteers
- 8,231 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Influenza
Pandemic Influenza Plasmid DNA Vaccines (Needle-Free)
The trial will enroll up to 47 subjects. Qualified normal healthy volunteers will be enrolled in the study to receive the vaccine or placebo vaccine.
- Trial name
- NCT00694213
- Testing
- VCL-IPM1, VCL-IPT1, PBS
- Where
- 3 sites in United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Vical
Influenza
Digital Storytelling to Reduce Pediatric Influenza Vaccination Disparities
While the COVID-19 pandemic has highlighted health disparities, Black children have unduly suffered and died from seasonal influenza for decades.
- Trial name
- NCT06274359
- Testing
- Digital storytelling
- Where
- 2 sites in United States
- Volunteers
- 398 people, healthy volunteers welcome
- Sponsor
- Denver Health and Hospital Authority
Prophylaxis: Influenza
Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects
The purpose of this study is to evaluate the immunologic equivalence of three consecutive lots of a cell based trivalent subunit influenza vaccine (TIVc), and to assess immunogenicity, safety and tolerability of the vaccine and…
- Trial name
- NCT02256488
- Testing
- TIVc_LOT A, TIVc_LOT B, TIVc_LOT C
- Where
- 24 sites in United States
- Volunteers
- 1,561 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza, Influenza Immunisation
Flublok or Fluzone With Advax-CpG55.2 or AF03
This is a Phase I, randomized, double blinded, clinical trial in up to 240 males and non-pregnant females, 18-45 years of age, inclusive, who are in good health and meet all eligibility criteria.
- Trial name
- NCT03945825
- Testing
- AF03, Delta Inulin-CpG55.2, Influenza Virus Quadrivalent Inactivated Vaccine
- Where
- 8 sites in United States
- Volunteers
- 241 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults
The purpose of this Phase 1/2 study is to generate sufficient safety and immunogenicity data of mRNA-1018 pandemic influenza candidate vaccines in healthy adults ≥18 years of age to enable the initiation of a large Phase 3 trial…
- Trial name
- NCT05972174
- Testing
- mRNA-1018 for H5N8, mRNA-1018 for H7N9, mRNA-1018 for H5 Only
- Where
- 27 sites in United States, United Kingdom
- Volunteers
- 1,504 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Influenza
Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years
The purpose of this study is to determine whether GSK's avian flu vaccine GSK 1557484A is immunogenic and safe when given to adults aged >=18 years.
- Trial name
- NCT00719043
- Testing
- A/turkey H5N1 vaccine, Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)
- Where
- 13 sites in United States, Canada
- Volunteers
- 841 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza Immunization, Healthy Volunteers
Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older
This is a Phase I, first-in-human, randomized, modified double-blind, active-controlled, dose-escalation study to assess the safety and immunogenicity of up to 3 dose levels of mRNA NA vaccines, administered as a single IM…
- Trial name
- NCT05426174
- Testing
- mRNA NA vaccine, High Dose Quadrivalent Influenza Vaccine
- Where
- 6 sites in United States
- Volunteers
- 233 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Exposure
Different Regimens in Influenza Postexposure Chemoprophylaxis in Children
Although the vaccination is the preferred method of influenza prevention, there are some occasions on which a postexposure prophylaxis (PEP) is required.
- Conditions
- Influenza, Exposure, Prevention
- Trial name
- NCT04297462
- Testing
- Oseltamivir 3 days, Oseltamivir 7 days
- Where
- Poland
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Centre of Postgraduate Medical Education
Normal Physiology
Studying Cell Immune Responses to a Live Flu Vaccine in Healthy Adults
Background: One form of the influenza vaccine is a nasal spray. It uses a live but weakened flu virus. Researchers want to better under how the live vaccine interacts with the body s immune system.
- Trial name
- NCT01730144
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Acute Respiratory Infection
Study to Assess Safety, Tolerability and Pharmacokinetics of XC221 in Healthy Volunteers
A double-blind, randomized, placebo-controlled, Phase I clinical study of the safety and tolerability of increasing doses of drug XC221 after single and repeated oral administration in healthy volunteers.
- Trial name
- NCT03459391
- Testing
- XC221 60 mg, XC221 200 mg
- Where
- Russia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- PHARMENTERPRISES LLC
Herpes Zoster
A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine
The aim of this study was to evaluate the immune response and safety of both GlaxoSmithKline Biologicals SA's (GSK's) herpes zoster (HZ) subunit (su) vaccine in healthy adults 50 years of age (YOA) and older and quadrivalent…
- Trial name
- NCT05047770
- Testing
- HZ/su, Flu D-QIV, mRNA-1273
- Where
- 46 sites in United States
- Volunteers
- 2,013 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Respiratory Infection Virus, COVID -19
Preparedness Through Respiratory Virus Epidemiology and Community Engagement
The CHARM network will be established through three primary institutions-Beth Israel Deaconess Medical Center (BIDMC), the University of California San Diego (UCSD), and the University of Washington (UW)-along with their…
- Conditions
- Respiratory Infection Virus, COVID -19, RSV, FLU
- Trial name
- PREVENT (NCT07147517)
- Testing
- Component A0, Component A1, Component A2
- Where
- 2 sites in United States
- Volunteers
- 25,000 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Influenza, Human
A Dose-ranging Pediatric Study of an Adjuvanted Pandemic Influenza Vaccine
This study is a pediatric dose-ranging study to evaluate the safety and immunogenicity of vaccination with different MF59-adjuvanted H5N1 vaccine formulations.
- Trial name
- NCT04669691
- Testing
- H5N1 antigen combined with MF59 adjuvant
- Where
- 7 sites in Estonia, Philippines
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Study to Evaluate Immunogenicity & Safety of an Investigational Influenza Vaccine in Adults
The objective of this study is to evaluate the immunogenicity and safety of GSK Biologicals' investigational vaccine GSK2340272A.
- Trial name
- NCT00975884
- Testing
- GSK investigational vaccine GSK2340272A
- Where
- 5 sites in France
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
No Conditions
Health Management Training to Enhance Influenza Vaccine Immunogenicity
The goal of this study is to assess the immunogenicity of inactivated influenza vaccination (IIV) in healthy elderly volunteers aged 50 years and older receiving one of two different health management trainings.
- Trial name
- NCT01256515
- Testing
- Health Education, Health Education Training
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
COVID-19 Immunization, Influenza Immunization
Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older
Study VBT00001 is planned to be a Phase 1/2, randomized, modified double-blind, active-controlled, multi-center study to be conducted in approximately 980 adults aged 50 years and older in the United States.
- Trial name
- NCT06695117
- Testing
- IIV-HD, rC19 (dose 1), IIV-HD + rC19 (dose 1)
- Where
- 12 sites in United States
- Volunteers
- 980 people, healthy volunteers welcome
- Sponsor
- Sanofi
Flu
Safety and Reactogenicity of a PAL Combined With Seasonal Flu Vaccine in Healthy Adults
This is a phase 1, research study is looking at the safety and acceptability of a new vaccine adjuvant (immune booster) called PAL when combined with the seasonal flu vaccine (Fluviral) to test the safety and effectiveness of new…
- Trial name
- NCT02188810
- Testing
- PAL, TIV
- Where
- Canada
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Folia Biotech Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.